Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ELOVL1 | Q9BW60 | 10/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2379699 | 0.76 | SMN1; SMN2 (0.50) | MAPTHTTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2380179 | 0.73 | MAPT (0.48) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL2379659 | 0.73 | ELOVL1 (0.48) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL9646405 | 0.73 | MAPT (0.62) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL10418621 | 0.73 | MAPT (0.62) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL23719194 | 0.71 | MAPT (0.68) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20250324 | 0.70 | ELOVL1 (0.77) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20249769 | 0.70 | ELOVL1 (1.00) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20249950 | 0.70 | ELOVL1 (1.00) | MAPTTSHRHTTHSD17B10L3MBTL1 | |
| SCHEMBL20241953 | 0.70 | ELOVL1 (1.00) | MAPTTSHRHTTHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | MAPT 72/4885TSHR 705/4885HTT 108/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | MAPT 73/4885TSHR 798/4885HTT 121/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | MAPT 72/4885TSHR 705/4885HTT 108/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | MAPT 72/4885TSHR 705/4885HTT 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.